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Abstract
Background: Compared to the golden standard glycation index of HbA1c, glycated albumin (GA) has potentials for
assessing insulin secretory dysfunction and glycemic fluctuation as well as predicting diabetic vascular complications.
However, the reference ranges of GA and a conversion equation need to be clearly defined. We designed this study to
determine the reference ranges in patients with normal glucose tolerance (NGT) based on conventional measures of
glycemic status and to devise a conversion equation for calculating HbA1c and GA in a Korean population.
Methodology/Principal Findings: In this multicenter, retrospective, cross-sectional study, we recruited antidiabetic drug-
naı¨ve patients with available glycemic variables including HbA1c, GA, and fasting plasma glucose regardless of glucose
status. For the reference interval of serum GA, 5th to 95th percentile value of GA in subjects with NGT was adopted. The
conversion equation between HbA1c and GA was devised using an estimating regression model with unknown break-
points method. The reference range for GA was 9.0–14.0% in 2043 subjects. The 95th percentile responding values for FPG,
and HbA1c were approximately 5.49 mmol/l, and 5.6%, respectively. The significant glycemic turning points were 5.868%
HbA1c and 12.2% GA. The proposed conversion equation for below and above the turning point were GA (%) = 6.960+
0.89636HbA1c (%) and GA (%) =29.609+3.7206HbA1c (%), respectively.
Conclusions/Significance: These results should be helpful in future studies on the clinical implications of high GA relative to
HbA1c and the clinical implementation of diabetes management.
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Introduction
Currently, HbA1c is the golden standard glycation index for use
in clinical practice and research [1]. However, it can be unreliable
in conditions affecting the lifespan of erythrocytes as well as the
clinical state in which glycemic control alleviates or deteriorates in
the short period. By overcoming the shortcomings of HbA1c,
glycated albumin (GA) has gained popularity as an useful index for
intermediate glycation and pathogenic protein [2].
Besides the role of GA as an intermediate glycation index,
several previous studies have suggested additional values of GA in
reference to HbA1c levels in assessing insulin secretory dysfunction
and fluctuating glycemic excursions [2–4]. Furthermore, elevated
serum GA levels as well as GA/HbA1c ratio have been suggested
to predict diabetic macrovascular complications [5]. Therefore, a
simple and accurate conversion equation determining GA using
HbA1c (and vice versa) would help physician for managing
patients with diabetes, although it remains to be clarified.
Previously, an easy but rough approximation (i.e., HbA1c=GA/
3) has been suggested [6]. However, GA levels are at unexpectedly
high levels, over HbA1c in patients with long duration of diabetes
or decreased insulin secretory function. Hence, this equation was
not acceptable for empirical adoption and lacked statistical
significance [7]. In addition, a similar but different concept of
the GA/HbA1c ratio confers additional clinical implications
regarding glucometabolic homeostasis and diabetic atherosclerosis
rather than simply converting GA to HbA1c [2,3,5].
Based on a previous study, where GA reportedly increased by
2.5–3.2% for every 1% increase in serum HbA1c (range: 6.5–
14.0% HbA1c) [4], we hypothesized that the proportion of HbA1c
to GA would differ in prediabetic and diabetic patients depending
on their glycemic status such as normal glucose tolerance (NGT),
pre-diabetes and type 2 diabetes (T2D). In this multicenter cross-
sectional study, our aims are to determine the reference ranges in
PLOS ONE | www.plosone.org 1 April 2014 | Volume 9 | Issue 4 | e95729
patients with NGT based on conventional measures of glycemic
status [8,9], and devise a conversion equation for calculating
HbA1c and GA in a Korean population.
Materials and Methods
Ethics Statement
This study was approved by the independent ethics committee/
institutional review board (IRB) at each study site (IRB of
Severance Hospital Yonsei University College of Medicine, Asan
Medical Center, University of Ulsan College of Medicine,
Kyunghee University Hospital, Kyunghee University Hospital at
Gangdong, Kangbuk Samsung Medical Center, Sungkyunkwan
University School of Medicine, and Samsung Medical Center,
Sungkyunkwan University School of Medicine, respectively). All
enrolled subjects provided written informed consent.
Study Population
Study subjects were recruited from outpatient clinics at 6 major
referral centers; a total of 2450 patients who were registered with
the health check-up program of Severance Hospital or the Newly
Detected Diabetes Registry in Asan Medical Center, Kyunghee
Hospital, Kangdong Kyunghee Hospital, Kangbuk Samsung
Hospital, Samsung Medical Center, and Severance Hospital were
recruited. All patients had their GA, HbA1c, and fasting plasma
glucose (FPG) levels measured. All study participantshad fasting C-
peptide levels of .0.5 ng/mL. We excluded patients without GA,
HbA1c, or FPG data and those with any of the following criteria
that might affect GA or HbA1c: hemoglobin (Hb) level ,12 g/dL
for women and ,13 g/dL for men; chronic kidney disease $
stage 3 (i.e., estimated glomerular filtration rate [eGFR] ,60 mL/
minute/1.73 m2 according to the Modification of Diet in Renal
Disease criteria [MDRD]); active thyroid disease; liver cirrhosis; or
nephrotic syndrome.
Clinical and Laboratory Examination
The body mass index (BMI) was calculated as weight in
kilograms divided by the square of height in meters. All blood
samples were obtained in the morning, following an overnight
fasting of at least 12 hours. Plasma glucose was measured by
the hexokinase method. Lipid parameters, including serum total
cholesterol, triglycerides, HDL cholesterol (HDL-C), directly-
measured LDL cholesterol (LDL-C) levels, and liver enzymes,
including aspartate aminotransferase (AST), alanine aminotrans-
ferase (ALT), and gamma-glutamyltransferase (GGT), were
measured using an enzymatic colorimetric method. Serum GA
was determined by an enzymatic method using an albumin-
specific proteinase, ketoamine oxidase and albumin assay
reagent (LUCICA GA-L, Asahi Kasei Pharma Co., Tokyo,
Japan), and a Hitachi 7699 Pmodule autoanalyzer (Hitachi
Instruments Service, Tokyo, Japan). The coefficient of variation
(CV) was 1.43%. HbA1c was measured by high-performance
liquid chromatography (HPLC) method. The reference intervals
of HbA1c were between 4.0% and 6.0%. HOMA of insulin
resistance (HOMA-IR) was calculated as the product of fasting
serum insulin (mU/ml) and FPG (mmol/l) concentrations,
divided by 22.5. HOMA of beta cell function (HOMA-beta)
was calculated according to the equation: HOMA-beta
(%) = (206fasting serum insulin)/(FPG-3.5). All enzyme activities
were measured at 37uC.
In this study, NGT was defined by the previously defined
criteria [8,9]: (1) FPG ,5.55 mmol/l and (2) HbA1c ,5.7%.
Statistical Methods
Continuous variables are expressed as the mean (6 standard
deviation [SD]). Categorical variables are expressed as proportions
(%). Demographic and biochemical characteristics of the study
population between the two arbitrarily defined groups in this study
were compared using independent t-test for continuous variables
and the chi-squared test for categorical variables. To determine
the relationship between serum GA and HbA1c levels according to
the deterioration of glucose tolerance, we performed the estimat-
ing regression model with unknown break-points as previously
described [10]. The normal reference interval of serum GA was
determined directly from the percentage of interest (i.e., the 5–95th
percentile of patients with NGT). The relationship between
glycemic parameters including FPG, GA, and HbA1c were
assessed by Pearson correlation analysis. The relevant values of
HbA1c and GA corresponding to specific FPG concentrations
were calculated using linear regression analysis after assigning
HbA1c and GA as dependent variables and FPG as independent
variables. R version 2.14.0 (R Foundation for Statistical Comput-
ing, Vienna, Austria, http://www.R-project.org) was used to
analyze the data. All p-values ,0.05 were considered statistically
significant.
Results
A total of 2043 subjects out of all that were recruited satisfied
the inclusion and exclusion criteria of this study. The clinical
characteristics of the study participants are shown in Table 1.
The mean age of the study subjects was 54.1611.1 years with
relatively even gender distribution (57.5% male). The mean
BMI was 25.063.3 kg/m2. When we fitted estimating regression
models with unknown break-points, serum GA levels were
drastically increased from HbA1C level of 5.868% (Fig. 1).
Based on this turning point of the slope, we classified the
subjects into two groups [group I, HbA1c ,5.9% (n= 736);
group II, HbA1c $5.9% (n= 1307)]. The subjects in group II
were statistically older (50.9610.4 vs. 56.0611.0 years years in
group I and group II, respectively; p,0.001) and more obese
(24.263.2 vs. 25.463.2 kg/m2 years in group I and group II,
respectively; p,0.001). The Hb concentration were similar
between the two groups (14.661.2 vs. 14.661.3 g/dL years in
group I and group II, respectively; p=0.949). Similar to our
previous reports [3,4], serum albumin levels were different
between the two groups (4.560.4 vs. 4.460.3 mg/dL in group I
and group II, respectively; p,0.001). The percentage of current
smoker was similar (22.8 vs. 21.0% dL in group I and group II,
respectively; p=0.391), but the blood pressure and glucometa-
bolic profiles, including FPG, GA, HOMA-IR, and HOMA-b,
were significantly higher in group II. Finally, significantly more
patients in group II were taking antihypertensive and antilipid
medications.
Table 2 shows the selected percentile concentrations for FPG,
GA, and HbA1c in patients with NGT. The 25–75th percentile
interval value was approximately 11.0–12.5% for GA, while the 5–
95th percentile interval was approximately 9.0–14.0% in patients
with NGT. In this study, the 95th percentile values for FPG, GA,
and HbA1c were approximately 99 mg/dL, 14.0%, and 5.6%,
respectively. The FPG and HbA1c values, according to the
individual percentile points, were almost exactly same between
sexes; but, the GA values were similar.
Figure 2 shows the overall correlations between HbA1c and GA
(Fig. 2A), FPG and HbA1c (Fig. 2B), and FPG and GA (Fig. 2C).
The positive correlation coefficient between HbA1c and GA was
the highest (r=0.915; p,0.001; Fig. 2A). Furthermore, FPG
Conversion Equation for HbA1c and GA
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concentrations demonstrated significant positive correlations to
both HbA1c (r=0.821; p,0.001, Fig. 2B) and GA (r=0.817; p,
0.001, Fig. 2C). Similar to previous studies [3,4], our results
indicated that FPG demonstrated a stronger correlation with
HbA1c over GA. The HbA1c and GA levels corresponding to
FPG were 5.9% and 12.6% for 5.55 mmol/l FPG, 6.3% and
14.0% for 6.11 mmol/l, and 6.8% and 16.0% for 6.94 mmol/l,
respectively.
Figure 1 shows the significant glycemic turning point, which
demonstrates an apparently linear trend above and below the
turning point from normal glucose to high glucose status. As
previously mentioned, we divided the patients into two groups
based on this turning point. Below and above 5.868% HbA1c, the
conversion equations obtained using the estimating regression
models with unknown breakpoints [10] for group I (HbA1c,
5.868%) and group II (HbA1c$5.868%) were GA (%) = 6.960+
0.8963 6HbA1c (%) and GA (%) =29.609+3.7206HbA1c (%),
respectively. The positive correlation coefficients for HbA1c and
GA were 0.135 (p,0.001) and 0.912 (p,0.001) for groups I and II,
respectively.
In table 3, the mean values of GA, GA/HbA1c ratio, and
FPG were analyzed according to the levels of HbA1c, which is
the standard glycation index used in clinical practice and
research. Based on the result regarding the turning point of
5.9% HbA1c in the continuous plots of GA and HbA1c (Fig. 1),
Figure 1. Estimating regression model analysis with unknown
break-points.
doi:10.1371/journal.pone.0095729.g001
Table 1. Clinical and biochemical characteristics of the study participants.
Total Group I (GI) Group II (GII) P value
Variables (n=2043) (n =736) (n=1307) (GI vs. GII)
Male (n, %) 1175 (57.5) 395 (53.7) 780 (59.7) 0.009
Age (years) 54.1 (11.1) 50.9 (10.4) 56.0 (11.0) ,0.001
BMI (kg/m2) 25.0 (3.3) 24.2 (3.2) 25.4 (3.2) ,0.001
WC (cm) 85.5 (8.9) 83.2 (8.7) 87.1 (8.6) ,0.001
Systolic BP (mmHg) 126.5 (16.4) 121.6 (15.1) 129.2 (16.4) ,0.001
Diastolic BP (mmHg) 78.0 (11.0) 76.2 (10.4) 78.9 (11.1) ,0.001
Current smoker (%) 17.0 22.8 21.0 0.391
Anti-HTN medication (%) 23.7 18.7 32.0 ,0.001
Anti-lipid medication (%) 14.2 15.0 21.1 0.002
FPG (mmol/l) 6.67 (2.09) 5.58 (0.67) 7.29 (2.36) ,0.001
HbA1c (%) 6.6 (1.6) 5.5 (0.2) 7.3 (1.7) ,0.001
GA (%) 15.4 (6.3) 11.9 (1.5) 17.4 (7.0) ,0.001
Hb (g/dl) 14.6 (1.3) 14.6 (1.2) 14.6 (1.3) 0.949
Protein (g/l) 7.1 (0.4) 7.0 (0.4) 7.1 (0.4) 0.001
Albumin (g/l) 4.5 (0.4) 4.5 (0.4) 4.4 (0.3) ,0.001
AST (U/l) 25 (15) 23 (10) 27 (18) ,0.001
ALT (U/l) 28 (27) 24 (15) 31 (31) ,0.001
GGT (U/l) 41 (46) 38 (48) 44 (44) 0.062
Total cholesterol (mmol/l) 4.95 (1.04) 4.94 (0.92) 4.96 (1.10) 0.636
Triglycerides (mmol/l) 1.66 (1.36) 1.42 (0.96) 1.79 (1.52) ,0.001
HDL-C (mmol/l) 1.35 (0.47) 1.39 (0.35) 1.34 (0.51) 0.009
LDL-C (mmol/l) 2.93 (0.93) 3.00 (0.82) 2.89 (0.99) 0.005
eGFR (ml/min/1.73 m2) 93.6 (23.6) 96.2 (28.1) 92.3 (21.0) 0.006
HOMA-IR 2.7 (2.3) 1.9 (1.2) 3.2 (2.6) ,0.001
HOMA-b (%) 69.1 (52.4) 76.1 (49.4) 65.0 (53.8) ,0.001
doi:10.1371/journal.pone.0095729.t001
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and 6.5% HbA1c, a well-known cut-off value for the diagnosis
of diabetes [8,9], we adopted both 5.9% and 6.5% HbA1c as
reference points for use in this study. In the ranges of non-
diabetes, mean values of GA/HbA1c ratio (2.16 to 2.17) were
similar. In the ranges of diabetes, however, the mean values of
GA/HbA1c ratio ranged from 2.34 to 3.17. Similar to previous
study [4], which included patients with T2D who were receiving
medications, the mean GA/HbA1c ratio (2.48–3.13) increased
as HbA1c increased.
Discussion
Current clinical guidelines for assessment of glycemic control
recommend self-monitoring of blood glucose (SMBG) by patient
and HbA1c as a part of hospital continuing care [8,9]. The latter is
thought to reflect the average glycemia over a few months and has
a strong predictive value for diabetes complications demonstrated
in the large-scale studies such as the Diabetes Control and
Complications Trial (DCCT) and U.K. Prospective Diabetes
Study (UKPDS) [11–13]. However, notwithstanding the effects of
erythrocyte turnover (hemolysis, blood loss) and hemoglobin
Table 2. Means and selected percentiles of GA, FPG, HbA1c, HOMA-IR and HOMA-b levels in subjects with NGT according to the
sex.
Variables Mean (SD) Percentile
5th 25th 50th 75th 95th
GA (%)
Total 11.5 (1.4) 9.0 11.0 11.3 12.5 14.0
Men 11.5 (1.2) 10.0 11.0 11.1 12.1 13.5
Women 11.6 (1.6) 9.0 10.9 11.4 12.5 14.2
FPG (mmol/l)
Total 5.03 (0.37) 4.27 4.83 5.11 5.33 5.49
Men 5.04 (0.37) 4.24 4.83 5.11 5.33 5.49
Women 5.03 (0.37) 4.25 4.83 5.11 5.33 5.49
HbA1c (%)
Total 5.4 (0.2) 5.0 5.4 5.5 5.6 5.6
Men 5.4 (0.2) 5.0 5.4 5.5 5.6 5.6
Women 5.4 (0.2) 5.0 5.3 5.5 5.6 5.6
HOMA-IR
Total 1.4 (0.9) 0.5 0.8 1.2 1.8 3.0
Men 1.5 (1.1) 0.4 0.8 1.2 1.9 4.3
Women 1.4 (0.7) 0.6 0.8 1.2 1.8 2.6
HOMA-b (%)
Total 85.3 (62.5) 28.5 47.2 70.9 100.1 213.9
Men 85.3 (59.6) 21.1 48.6 70.7 99.5 224.9
Women 85.4 (64.8) 31.4 45.7 71.6 101.5 190.4
The number of men, and women tested were 107, and 155, respectively.
doi:10.1371/journal.pone.0095729.t002
Figure 2. Correlation between HbA1c and GA (A), FPG and HbA1c (B), and FPG and GA (C).
doi:10.1371/journal.pone.0095729.g002
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variants [6], HbA1c is limited because it does not provide a
measure of glycemic variability or hypoglycemia especially in
patients with both T2D and severe insulin deficiency [8]. Because
of these challenges, it is recommended for glycemic control to be
judged by the combination of the results of SMBG and the HbA1c
for patients prone to glycemic variability [8,14]. These unmet
needs have allowed GA to gain popularity among physicians.
Growing evidence demonstrates that GA, in conjunction with the
GA/HbA1c ratio might be more accurate than HbA1c alone for
assessing insulin secretory dysfunction, which resulted in glycemic
fluctuation and variability [2–4] and can be used to predict
atherosclerosis [5,15]. Considering these potentials of GA,
accurate interpretation of GA on the basis of HbA1c such as
increased GA/HbA1c ratio or unexpected high GA levels over the
HbA1c one is of paramount importance for assessing the
pathophysiologic changes [2–4] and predicting the diabetic
complications in patients with T2D [5]. However, an accurate
conversion equation that takes into account the GA and HbA1c
values (and vice versa) has not been developed for use in Korean
populations.
The aim of the present study was to develop a simple equation
for converting HbA1c to GA in a Korean population. By
establishing expected GA levels from HbA1c, we could get
additional information on the glycemic fluctuation, insulin
secretory dysfunction and pro-atherogenic condition in subjects
with T2D in whom the laboratory levels of GA would be above the
calculated GA levels. The present study demonstrates 3 main
findings. First, the 5.0th–95.0th percentile reference interval for GA
was 9.0% to 14.0% while adopting the cut-off values of impaired
glucose tolerance of both FPG levels $5.55 mmol/l, and HbA1c
levels $5.7%. Second, we noted a significant glycemic turning
point at 5.868% HbA1c and an apparently linear slope (both
below and above this point) on continuous plots for GA and
HbA1c in patients with various levels of glucose intolerance (the
corresponding GA value was 12.2%). Third, we devised the
following conversion equations for GA and HbA1c in groups I
(HbA1c,5.868%) and II (HbA1c$5.868%):GA (%) = 6.960+
0.8963 6HbA1c (%) and GA (%)=29.609+3.7206HbA1c (%),
respectively.
Regarding the reference values for GA, it ranged between 11.9–
15.8% (mean 62 SD) in a healthy American population of both
white and black patients without a known history of diabetes in
North Carolina (n = 201 patients); this range was determined using
the 75-g oral glucose tolerance test (OGTT) and demonstrated a
significant racial difference [16]. In a study with a limited number
of Italian patients (n = 32), the GA of the normal control group
ranged between 11.7–16.9% (2.5–97.5th percentile) [17]. In a
study conducted by the Japan Diabetes Society, the reference
range for GA determined using 75-g OGTT in a selected Japanese
reference population (n= 699 patients) was 12.3–16.9% (mean 62
SD) [18]. In Chinese patients with NGT (n= 380), the 2.5–97.5th
percentile was 10.8–17.1% GA [19]. On the other hand, the
reference range (9.0–14.0% GA corresponding to the 5–
95thpercentile) in this population of Korean patients (n = 2043)
did not exactly correspond to other Asian ethnicities, including
Japanese and Chinese populations. This could be explained by the
different FPG cutoff values that were used to define NGT (,
110 mg/dL in Japanese population) [18] and the fact that 75-g
OGTT was not used to assess our Korean population. In addition,
we included patients with both FPG,5.55 mmol/l and HbA1c,
5.7%. Similar to the racial differences noted in the American
population, ethnic differences are debatable and require further
investigations. Furthermore, there are no international standards
for GA or any external quality assessment programs. Therefore,
international standardization is clearly required for use in both
clinical practice and research.
We used 2 steps to develop our conversion equation. In the first
step, we identified a significant glycemic turning point (5.868%
HbA1c; Fig. 1) using the continuous plots of GA and HbA1c. In
the second step, we calculated separate conversion equations for
both above and below this turning point. A plausible explanation
for this turning point might be the inert structural characteristics
and different glycation processes of both albumin and Hb. Serum
albumin is directly exposed to high glucose levels, while Hb, which
resides within erythrocytes, is indirectly exposed to high glucose.
Previous studies reported that the in vivo nonenzymatic glycation
rate of albumin is approximately 9 times that of human Hb [20],
and albumin glycation proceeds 10 times more quickly than Hb
glycation [21]; these findings could partially account for the
turning point [22]. In addition, glycemic fluctuations, which are
observed in patients with high glucose status and decreased insulin
secretory function [3,4] affect plasma proteins (such as albumin)
more easily than intracellular proteins (such as Hb); this can result
in higher GA levels, even in newly diagnosed T2D patients. As far
as we know, this might be the first attempt to devise a conversion
equation for GA and HbA1c based on the glycemic turning point.
The proposed conversion equation (GA=29.609+3.720 6
HbA1c [%]) for newly diagnosed T2D patients corresponds well
to our previously reported equation (GA=28.01+3.666HbA1c
[%]) [4].
There are a few important limitations to our study that warrant
consideration, besides its retrospective nature. First, the lack of 2-
Table 3. Mean values of glycemic parameters according to HbA1c.
HbA1c (%) N (%) HbA1c (%) GA (%) GA/A1c FPG (mmol/l)
HbA1c,5.9 736 (36.0) 5.5 11.9 2.16 5.58
5.9#HbA1c,6.5 575 (28.1) 6.1 13.3 2.17 6.04
6.5#HbA1c,7.5 370 (18.1) 6.8 16.0 2.34 6.90
7.5#HbA1c,8.5 143 (7.0) 7.8 18.7 2.38 7.80
8.5#HbA1c,9.5 71 (3.5) 8.9 23.6 2.65 9.14
9.5#HbA1c,10.5 49 (2.4) 10.0 26.9 2.70 9.97
10.5#HbA1c,11.5 41 (2.0) 11.0 29.7 2.71 11.47
11.5#HbA1c,12.5 29 (1.4) 11.8 35.6 3.02 11.53
HbA1c$12.5 29 (1.4) 13.6 43.3 3.17 15.25
doi:10.1371/journal.pone.0095729.t003
Conversion Equation for HbA1c and GA
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hour OGTT is a limitation because it may have resulted in the
inclusion of patients with impaired glucose tolerance to the NGT
group. Second, although we measured plasma GA at each hospital
under the regulation of the US National Glycohemoglobin
Standardization Program, it would be better if the GA measure-
ments were performed by single central laboratory. Lastly, this
study included only Korean patients, preventing generalization
with other ethnic populations.
The present study suggests a reference range of 9.0–14.0% GA
for Korean patients. Based on the continuous plots of GA and
HbA1c in patients with normal and high glucose status, the
significant glycemic turning points are 5.868% HbA1c and 12.2%
GA. The proposed conversion equations below and above the
turning point are GA (%)= 6.960+0.89636HbA1c (%) and GA
(%) =29.609+3.720 6 HbA1c (%), respectively. Using the
equation that we proposed, the differences between measured
GA level and calculated GA level could be identified. These results
should be helpful in future studies on investigating the clinical
implication of GA as a glycemic index in specific patients with
unexpected high GA levels over the HbA1c and the clinical
implementation of diabetes management using GA.
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